PR Newswire
Labcorp® Plasma CompleteTM offers oncologists a highly sensitive and specific genomic profiling solution from a simple blood draw
BURLINGTON, N.C., Feb. 24, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the clinical availability of Labcorp® Plasma CompleteTM, a circulating tumor DNA (ctDNA)-based comprehensive genomic profiling solution for patients with advanced solid tumors. The liquid biopsy test enables oncologists to perform comprehensive genomic profiling to inform personalized treatment decisions – all from a simple blood draw.
Company Provides 2025 Guidance
Results from Continuing Operations versus last year:Revenue: Q4 of $3.33 billion vs $3.03 billion; Full year of $13.01 billion vs $12.16 billionDiluted EPS: Q4 of $1.70 vs $(1.95); Full year of $8.84 vs $4.33Adjusted EPS: Q4 of $3.45 vs $3.30; Full year of $14.57 vs $13.56Free Cash Flow: Q4 of $665.1 million vs $412.4 million; Full year of $1.10 billion vs $748.7 millionAnnounced 10 transactions and launched new innovative tests meeting significant unmet medical needs in key specialty areas in full year 2024Full-Year 2025 Guidance:Revenue of $13.88 billion to $14.05 billion; midpoint growth of 7.4%Adjusted EPS of $15.60 to $16.40; midpoint growth of 9.8%Free Cash Flow of $1.10 billion to $1.25 billion; midpoint growth of 7.2%
BURLINGTON, N.C., Jan. 10, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will participate in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, at 3:45 p.m. (PT).
A live audio webcast of the fireside chat will be available via the Company Investor Relations website at ir.Labcorp.com and archived for replay.
BURLINGTON, N.C., Jan. 8, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 12, 2025, to stockholders of record as of the close of business on February 27, 2025.
BURLINGTON, N.C., Jan. 8, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter of 2024 before the market opens on Thursday, February 6, 2025. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.
New test supports public health preparedness efforts and testing infrastructure amid multistate outbreak of H5 bird flu in poultry and dairy cows
BURLINGTON, N.C., Dec. 17, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the commercial availability of its new H5 bird flu molecular test to aid in the diagnosis of human infection with H5 bird flu. The test is available in the United States to physicians to order for patients suspected of infection with the H5N1 virus.*
Research to be presented in a joint poster session with Labcorp at the 2024 San Antonio Breast Cancer Symposium
BOSTON and BURLINGTON, N.C., Nov. 26, 2024 /PRNewswire/ -- Outcomes4Me Inc., the developer of the first and only end-to-end, actionable cancer platform, announced today it has been selected to present the results of a biomarker awareness study, conducted with Labcorp, a global leader of innovative and comprehensive laboratory services, at the prestigious 2024 San Antonio Breast Cancer Symposium (SABCS) on December 13, 2024. SABCS is the preeminent conference for sharing cutting-edge breast cancer research with healthcare professionals, researchers, and patient advocates worldwide.
Research to be presented in a joint poster session with Labcorp at the 2024 San Antonio Breast Cancer Symposium
BOSTON and BURLINGTON, N.C., Nov. 26, 2024 /PRNewswire/ -- Outcomes4Me Inc., the developer of the first and only end-to-end, actionable cancer platform, announced today it has been selected to present the results of a biomarker awareness study, conducted with Labcorp, a global leader of innovative and comprehensive laboratory services, at the prestigious 2024 San Antonio Breast Cancer Symposium (SABCS) on December 13, 2024. SABCS is the preeminent conference for sharing cutting-edge breast cancer research with healthcare professionals, researchers, and patient advocates worldwide.
Julia Wang Named Chief Financial Officer Beginning December 2, 2024
BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.
Updates Full-Year Guidance
Results from Continuing Operations for third quarter 2024 versus last year:Revenue: $3.28 billion versus $3.06 billionDiluted EPS: $2.00 versus $2.11Adjusted EPS: $3.50 versus $3.38Free Cash Flow: $162 million versus $171 millionUpdated Full-Year 2024 Guidance:Revenue range of 6.6% to 7.3%; midpoint unchangedAdjusted EPS range of $14.30 to $14.70; midpoint down $0.10, due to the negative impact from weather of approximately $0.15Free Cash Flow of $850 million to $980 millionAnnounced three new acquisitions/lab management agreements, and closed two acquisitions during the quarter that support growth initiativesLabcorp to serve as the exclusive NOWDiagnostics (NOWDx) distributor for clinical testing in the U.S., offering First to Know® Syphilis Test nationwide
BURLINGTON, N.C., Oct 10, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it has expanded its portfolio of sexually transmitted infection (STI) testing options to include the First to Know® Syphilis Test, the first over-the-counter blood test granted market authorization by the U.S. Food & Drug Administration (FDA) that can be performed by both physicians and patients.
BURLINGTON, N.C., Oct. 10, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on December 13, 2024, to stockholders of record as of the close of business on November 26, 2024.
About LabcorpLabcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 67,000 employees serve clients in approximately 100 countries, provided support for 84% of the new drugs and therapeutic products approved in 2023 by the FDA, and performed more than 600 million tests for patients around the world. Learn more about us at www.labcorp.com.
BURLINGTON, N.C., Sept. 24, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of 2024 before the market opens on Thursday, October 24, 2024. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.
New solution is the first holistic program available in a digital app to help women manage the postpartum period
BOSTON, Sept. 18, 2024 /PRNewswire/ -- Ovia Health by Labcorp (Ovia) today announced the expansion of its women's health solutions to include a personalized, comprehensive Postpartum Experience – a 12-month program designed to help women manage multiple aspects of the postpartum period through personalized recovery modes, symptom tracking and alerts, and mental health support.
BURLINGTON, N.C., Sept. 16, 2024 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH) (Labcorp) announced today that its wholly owned subsidiary, Laboratory Corporation of America Holdings (LCAH), has priced its offering of $2,000,000,000 in senior notes (the Offering). The Offering consists of three tranches: $650,000,000 aggregate principal amount of 4.350% Senior Notes due 2030 (the 2030 Notes), $500,000,000 aggregate principal amount of 4.550% Senior Notes due 2032 (the 2032 Notes) and $850,000,000 aggregate principal amount of 4.800% Senior Notes due 2034 (the 2034 Notes and, together with the 2030 Notes and the 2032 Notes, the Notes). The Notes will bear interest from September 23, 2024, payable semi-annually on April 1 and October 1, commencing on April 1, 2025. The 2030 Notes will be issued at 99.931% of par value and will mature on April 1, 2030. The 2032 Notes will be issued at 99.608% of par value and will mature on April 1, 2032. The 2034 Notes will be issued at 99.755% of par value and will mature on October 1, 2034. The Offering is expected to close on September 23, 2024, subject to the satisfaction of customary closing conditions. The Notes will be LCAH's senior unsecured obligations, will rank equally with LCAH's existing and future senior unsecured debt and will be fully and unconditionally guaranteed by Labcorp.
Enhances Labcorp's laboratory services network and expands access to its clinical services
BURLINGTON, N.C. and MIAMI, Sept. 16, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today the completion of Labcorp's acquisition of select assets of BioReference Health, a wholly owned subsidiary of OPKO Health. The transaction is expected to provide patients, physicians and customers with greater access to Labcorp's comprehensive, high-quality laboratory services, scientific expertise and expanded testing capabilities in key regions across the country.
BURLINGTON, N.C., Sept. 3, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a presentation at the Baird 2024 Global Healthcare Conference on Tuesday, September 10, at 3:10 p.m. ET.
About LabcorpLabcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 67,000 employees serve clients in approximately 100 countries, provided support for 84% of the new drugs and therapeutic products approved in 2023 by the FDA and performed more than 600 million tests for patients around the world. Learn more about us at www.Labcorp.com.
Extends Labcorp's leadership in genetic testing solutions for oncology and select rare diseases
BURLINGTON, N.C., Aug. 5, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the completion of its acquisition of select assets of Invitae (OTC:NVTAQ), a leading medical genetics company. Together, Labcorp and Invitae will support patients, clinicians and pharmaceutical partners across the continuum of care, including therapy development, patient diagnosis and personalized care.
PGDx elio™ plasma focus Dx is the industry's first and only kitted, pan-solid tumor liquid biopsy test that enables tumor mutation profiling – all from a simple blood draw
BURLINGTON, N.C., Aug. 2, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it has received De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) for PGDx elio™ plasma focus Dx – the industry's first and only kitted, pan-solid tumor liquid biopsy test.
Updates Full-Year Guidance
Results from Continuing Operations for second quarter 2024 versus last year:Revenue: $3.22 billion versus $3.03 billionDiluted EPS: $2.43 versus $1.74Adjusted EPS: $3.94 versus $3.42Free Cash Flow: $432.9 million versus $58.2 millionUpdated Full-Year 2024 Guidance:Revenue range of 6.4% to 7.5%, includes Invitae impact of ~1.0%Adjusted EPS range of $14.30 to $14.90, includes Invitae dilution of ~$0.40Free Cash Flow of $0.85 billion to $1.00 billion, includes Invitae cash usage of ~$150 millionShare repurchase authorization increased by $1.0 billion to $1.4 billionLaunched important new tests in specialty testing areasIntroduced Labcorp Global Trial Connect, a suite of central laboratory solutions aimed to accelerate clinical trialsDie hier zur Verfügung gestellten Informationen unterliegen keiner redaktionellen Bearbeitung. Die Aufbereitung erfolgt vollautomatisch und wird durch Zusatzinformationen und weiterführende Recherchemöglichkeiten angereichert. Ziel der Inhalte ist die schnelle und unkomplizierte Versorgung der Informationssuchenden mit den für sie relevanten Informationen. Durch eine Rückverlinkung auf den Informationsanbieter und -eigentümer ist sichergestellt, dass die hier aufbereiteten Daten bei Bedarf mit den Quellinformationen abgeglichen werden können. Das Newsboard zeigt keine Informationen in Echtzeit. Diese bitten wir bei Bedarf beim Börsenbetreiber abzurufen. Es besteht kein Anspruch auf Vollständigkeit. Hochverfügbarkeit kann nicht gewährleistet werden. Sollten Sie Fehler in der Funktionsweise bemerken, teilen Sie uns diese über das weiter unten befindliche Formular "Report a Bug" mit.
RAW DATA PROCESSING bedeutet, dass Rohdaten verarbeitet werden, ohne den Inhalt zu verändern. Um die Interpretation der Information im Sinne der Nutzbarkeit zu verbessern, werden die Daten ergänzt.
Hinweis: Über das Newswire-Crosslink-Panel im oberen Bereich gelangen Sie schnell und bequem zu weiteren Informationsquellen. Im Terminalview sind die Nachrichten auf Unternehmensebene gefiltert und ermöglich darüber gezielte Recherchen.
Wir bedanken uns im Namen der Trading-Community bei den Betreibern der Handelsplätze für die Bereitstellung von Informationsdiensten.